Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21508857 | 1.00 | CNR2 (0.32) | CNR2CASP1 | |
| SCHEMBL14979993 | 1.00 | CNR2 (0.32) | CNR2CASP1 | |
| SCHEMBL8209861 | 0.93 | CNR2 (0.31) | CNR2CASP1 | |
| SCHEMBL21486274 | 0.93 | CNR2 (0.31) | CNR2CASP1 | |
| SCHEMBL3306435 | 0.93 | CNR2 (0.31) | CNR2CASP1 | |
| SCHEMBL731017 | 0.88 | CNR2 (0.31) | CNR2 | |
| SCHEMBL20477494 | 0.88 | CNR2 (0.31) | CNR2 | |
| SCHEMBL731018 | 0.88 | CNR2 (0.31) | CNR2 | |
| SCHEMBL15424652 | 0.88 | CNR2 (0.32) | CNR2 | |
| SCHEMBL19174544 | 0.88 | CNR2 (0.32) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461107-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461107-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110046161-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046161-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2271345-A1 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009134624-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134624-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046161-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | CNR2 4458/4885CASP1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.